Skip to content
Search

Latest Stories

'Pharmacies could support NHS plan on future of vaccination services with additional remuneration'

In its response to NHS England's consultation on 'the future of vaccination services’, the Pharmaceutical Services Negotiating Committee (PSNC) has suggested that a wider range of NHS vaccinations being available from community pharmacies could support the achievement of increased vaccination levels.

PSNC said: “Any additional services that contractors could provide can only be considered with additional remuneration above the current global sum in the community pharmacy contractual framework to ensure that the services are adequately resourced.”


Alastair Buxton, director of NHS Services at PSNC, said: “We’ve always known, and the evidence supports this, that community pharmacies are one of the most popular and accessible places for people to receive a range of vaccinations.

“The NHS was slow to take advantage of this at the start of the Covid-19 pandemic, so we welcome this consultation from them to bring together a wide range of views on the topic.

“In the longer-term, if the right funding and support is in place, many pharmacies could help deliver a much wider range of NHS vaccination programmes – giving the public the convenience and service that they want, and taking pressure off our general practice colleagues. It makes perfect sense, and we look forward to the NHS response to this consultation.”

The consultation is designed to help NHS England deliver a future vaccination strategy. It aims to support local teams that plan and deliver vaccinations to build on the NHS COVID-19 vaccination programme’s success and learning; and provide responsive, accessible, convenient and high quality NHS vaccination services to people and their families.

The PSNC response highlights the following:

  • Community pharmacy contractors take a responsive approach to the needs of local communities, by providing access to services across opening hours that are generally longer than those in other parts of primary care;
  • The sector has shown the ability to step up in times of need and to provide surge capacity in the provision of clinical services;
  • Opportunities for distributing centrally procured vaccines to pharmacies could be explored through contracts with pharmaceutical wholesalers;
  • Enabling the increasing use of interoperable IT systems would support wider levels of vaccination through pharmacies and provide NHS England with real-time data;
  • The use of national protocols to authorise the administration of vaccines, using a team-based approach beneficially maximises the provider’s use of skill mix;
  • The use a National Enhanced Service for the commissioning of pharmacy vaccination services could support some national standardisation, where it is helpful and appropriate, while allowing local decisions on the best placed pharmacies to meet the needs of the local population;
  • A range of vaccinations available from a well distributed network of NHS providers, such as community pharmacy, will help to drive improved uptake; and
  • Pharmacy’s location at the heart of local communities means they are in a strong position to reach out to the less well-served members of the public living in their area.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less